Brind.

John Leonard, President and CEO of Intellia Therapeutics, discussed the Phase 3 results for Lonvo-Z.

2 reports, 2 independent Updated Sep 9
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

John Leonard, President and CEO of Intellia Therapeutics, discussed the Phase 3 results for Lonvo-Z.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Priority Review of BLA for lonvo-z1 source
  2. Intellia CEO John Leonard discussed the Phase 3 results for Lonvo-Z.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped